Product Name
Ipigrix® 20 mg
Pharmacological Properties
The main pharmacological effects of ipidacrine include:
There are insufficient clinical data regarding the safety of this medicine in children.
Indications
Dosage and Administration
The tablets are taken orally with water.
The dose and duration of treatment are determined individually according to the severity of the disease.
Peripheral nervous system disorders, myasthenia gravis, and myasthenic syndrome:
For a 10 mg dose, another dosage form (Ipigrix® 5 mg/ml solution for injection) should be used.
Prevention of myasthenic crisis:
Memory disorders (Alzheimer's disease and other forms of dementia):
Intestinal atony:
No dose adjustment is required in elderly patients or in patients with hepatic and/or renal impairment.
If you miss a dose, take it as soon as you remember. Do not take a double dose to make up for the missed dose.
Contraindications
- Restoration and stimulation of neuromuscular transmission;
- Restoration of impulse conduction in the peripheral nervous system after blockade caused by trauma, inflammation, local anesthetics, antibiotics, potassium chloride, and other factors;
- Enhancement of smooth muscle contractility in response to all agonists except potassium chloride;
- Mild stimulation of the central nervous system combined with slight sedative effects;
- Improvement of memory.
- Peripheral nervous system disorders (neuritis, polyneuritis, polyneuropathy, polyradiculoneuropathy, myasthenia gravis, and myasthenic syndrome);
- Bulbar paralysis and paresis;
- Recovery period after organic CNS lesions accompanied by motor impairment;
- Demyelinating diseases of the central nervous system (as part of combination therapy);
- Memory disorders of various origins, including Alzheimer's disease and other forms of senile dementia;
- Intestinal atony.
- 10–20 mg, 1–3 times daily;
- Treatment duration: 1–2 months;
- If necessary, treatment courses may be repeated after 1–2-month intervals.
- Initially, 15–30 mg is administered parenterally (Ipigrix® 15 mg/ml solution for injection);
- Treatment is then continued with tablets at 20–40 mg (1–2 tablets), 5–6 times daily;
- Maximum daily dose: 240 mg.
- The dose and duration of therapy are determined individually;
- Maximum daily dose: 200 mg;
- Treatment duration: from 1 month to 1 year.
- 20 mg, 2–3 times daily for 1–2 weeks.
- Hypersensitivity to ipidacrine or any component of the product;
- Epilepsy;
- Extrapyramidal disorders with hyperkinesia;
- Angina pectoris;
- Severe bradycardia;
- Bronchial asthma;
- Vestibular disorders;
- Active gastric or duodenal ulcer disease;
- Intestinal or urinary tract obstruction;
- Pregnancy;
- Breastfeeding.
